Laurie Bergman
Analyst · Citi
Thank you, Kurt, and good morning, everyone. Before reviewing the quarter, I'd like to say how pleased I am to have joined Ecovyst. Over the past couple of months, I've spent time getting to know our businesses, our people and our opportunities. And what has stood out to me is the strength of our capabilities and customer relationships. I'm excited to work with Kurt and the team to build on those strengths with a focus on disciplined execution, cash generation and long-term value creation. With that, let me turn to our quarterly results. Turning to Slide 7. Key highlights for the quarter included higher volume for regenerated sulfuric acid and favorable pricing with sales and adjusted EBITDA up year-over-year. Turning to the details on the third quarter on Slide 8. Third quarter sales were $309 million, up $104 million or 51% compared to the year-ago quarter. The increase was driven by higher sales for both virgin and regenerated sulfuric acid, favorable pricing, the contribution from the Calabrian business acquired on June 30 and higher average pricing associated with the pass-through of higher sulfur costs of approximately $67 million. Adjusted EBITDA of $61 million was up over 6%, reflecting the volume and pricing dynamics contributing to the sales increase. These factors were partially offset by higher manufacturing costs, the impact of general inflation and higher transportation costs. For the third quarter, the adjusted EBITDA margin was 19.8% compared to 28.1% in the year-ago quarter. The decrease reflects the pass-through effect on sales of significantly higher sulfur costs. Excluding the pass-through effect of higher sulfur costs on sales of approximately $67 million, the third quarter adjusted EBITDA margin would have been approximately 550 basis points higher. Slide 9 provides an adjusted EBITDA bridge, highlighting the primary factors for the increase in third quarter 2026. The pass-through effect of higher sulfur costs on sales was approximately $67 million in the third quarter. Excluding the pass-through, net pricing increased $5 million, and this was primarily associated with favorable pricing for both virgin and regenerated sulfuric acid. Higher volume contributed $15 million to the period-over-period increase in adjusted EBITDA. These factors were partially offset by higher manufacturing costs, higher turnaround costs and activity compared to the third quarter of 2025, higher employee-related costs, including inflation costs, costs associated with the acquisition of Calabrian and less favorable fixed cost absorption. Turning to cash and leverage on the next slide. Cash generation remained positive in the third quarter with year-to-date adjusted free cash flow of $32.4 million. Recall that free cash flow generation this year reflects both higher capital expenditures associated with the ongoing expansion of our Gulf Coast storage and logistics and the working capital impact of significantly higher sulfur costs on inventory and accounts receivable. During the quarter, we maintained a strong liquidity position with available liquidity of $167 million at September 30, comprised of cash and cash equivalents of $71 million and availability under our ABL facility of $96 million. Lastly, our net debt leverage ratio was 2.1x, essentially unchanged compared to June 30, and this includes only 1 quarter for Calabrian for the trailing 12-month period. I'll now turn to our outlook and revised guidance for 2026. Sulfur prices continued to rise in the third quarter. However, we expect modestly lower sulfur costs for the balance of the year, reflecting a $90 decrease in the Tampa Sulfur Index from $705 per ton to $615 per ton. We still expect the full year pass-through effect of sulfur costs on sales to be approximately $220 million. Taking into account the positive demand and favorable pricing we have seen for the first 9 months of this year and factoring in the expected pass-through effect of higher sulfur costs, we now expect our full year 2026 sales to be in the range of $1.05 billion to $1.07 billion, up modestly from our previous guidance of $1.02 billion to $1.06 billion. Reflecting our strong year-to-date performance, stable demand and favorable net pricing, we are raising our full year 2026 adjusted EBITDA guidance to a range of $208 million to $212 million, a 4.5% increase at the midpoint from our prior guidance range of $195 million to $207 million. This outlook also reflects the shift into early next year of a turnaround previously scheduled for the fourth quarter with a cost of approximately $3 million. We are also raising our adjusted free cash flow guidance to a range of $50 million to $60 million, up from $45 million to $55 million. Our expectation for the full year 2026 interest expense is now at $19 million to $21 million. And we now expect capital expenditures to be $90 million to $95 million with the midpoint up slightly from our prior guidance of $85 million to $95 million. Depreciation and amortization is now projected at $84 million to $88 million, up from our prior guidance of $80 million to $84 million. We continue to expect our full year effective tax rate to be in the mid-20% range, and we now expect adjusted net income to be in the range of $70 million to $85 million with adjusted diluted net income per share of $0.63 to $0.77, up from $0.58 to $0.72. As we move to the next slide, I'll provide directional guidance for the fourth quarter. Given the high refinery utilization that Kurt alluded to, we expect fourth quarter volume for regenerated sulfuric acid to be up compared to the year-ago quarter. While we expect fourth quarter virgin sulfuric acid volume to be lower than in the fourth quarter of 2025, this reflects a strong prior year comparison. When unplanned refinery outages reduced regenerated sulfuric acid volume in the fourth quarter of 2025, we were able to shift our capacity to capture attractive spot sales of virgin sulfuric acid. With refinery utilization running high this year, we expect that capacity to remain focused on serving our regeneration customers. Regarding our turnaround schedule, as previously noted, we are deferring the turnaround previously planned for the fourth quarter into early 2027. The projected cost of this turnaround was approximately $3 million. And as noted in the chart, we expect to execute 6 turnarounds at our sulfuric acid plants in 2027. Overall, for the fourth quarter, we anticipate adjusted EBITDA to land in the range of $54 million to $58 million. I will now hand the call back to Kurt for some closing remarks.